Year None2025202420232022202120202019201820162015 Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update Mar 31, 2025 Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102 Mar 26, 2025 Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results Mar 25, 2025 Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC Feb 05, 2025
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update Mar 31, 2025
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102 Mar 26, 2025
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC Feb 05, 2025
